Premium
Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes
Author(s) -
Chaplin Steve,
Bain Stephen
Publication year - 2015
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1393
Subject(s) - dulaglutide , medicine , type 2 diabetes , exenatide , glucagon like peptide 1 receptor , agonist , diabetes mellitus , adverse effect , pharmacology , endocrinology , receptor
Dulaglutide is a once‐weekly GLP‐1 receptor agonist for the treatment of type 2 diabetes. Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Stephen Bain discusses its place in therapy.